Pharmaceutical

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company…

2 weeks ago

UniDoc Receives Order for Health Cubes

Three units for demonstration within Verizon Innovation Labs VANCOUVER, BC / ACCESS Newswire / November 25, 2025 / UniDoc Health…

2 weeks ago

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will…

2 weeks ago

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

Internationally recognized colorectal surgeon Steven D. Wexner, MD, FACS, FRCS, to discuss the clinical and economic burden of surgical site…

2 weeks ago

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV Valuation

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement…

2 weeks ago

As UnitedHealthcare Scales Back Traditional RPM, Addison(R) Virtual Caregiver Signals the Next Phase of Home-Based Care

Electronic Caregiver's 24/7 virtual caregiving platform steps forward just as payers move away from low-engagement, device-only monitoring. LAS CRUCES, NM…

2 weeks ago

LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment

Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to…

2 weeks ago

Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS

Publication details large multicenter clinical trial demonstrating significant reductions in IBS symptoms through inFoods IBS guided dietary therapy IRVINE, Calif.,…

2 weeks ago

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing…

2 weeks ago

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

WAYNE, Pa., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing…

2 weeks ago